Viking Therapeutics Inc
VKTX
Market Cap$3.3B
Close$
$0.23
99.1% downside
Current Fair Value
99.1% downsideOvervalued by 99.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.30 Billion |
|---|---|
| Enterprise Value | $3.26 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-1.01 |
| Beta | 0.83 |
| Outstanding Shares | 112,069,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -25.66 |
|---|---|
| PEG | -240.31 |
| Price to Sales | - |
| Price to Book Ratio | 3.94 |
| Enterprise Value to Revenue | 7478.17 |
| Enterprise Value to EBIT | -24.32 |
| Enterprise Value to Net Income | -33 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Viking Therapeutics Inc
CEO: Brian Lian